RT Journal Article
T1 Prospective analysis of circulating metabolites and endometrial cancer risk.
A1 Dossus, Laure
A1 Kouloura, Eirini
A1 Biessy, Carine
A1 Viallon, Vivian
A1 Siskos, Alexandros P
A1 Dimou, Niki
A1 Rinaldi, Sabina
A1 Merritt, Melissa A
A1 Allen, Naomi
A1 Fortner, Renee
A1 Kaaks, Rudolf
A1 Weiderpass, Elisabete
A1 Gram, Inger T
A1 Rothwell, Joseph A
A1 Lécuyer, Lucie
A1 Severi, Gianluca
A1 Schulze, Matthias B
A1 Nøst, Therese Haugdahl
A1 Crous-Bou, Marta
A1 Sanchez-Perez, Maria-Jose
A1 Amiano, Pilar
A1 Colorado-Yohar, Sandra M
A1 Gurrea, Aurelio Barricarte
A1 Schmidt, Julie A
A1 Palli, Domenico
A1 Agnoli, Claudia
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Mattiello, Amalia
A1 Vermeulen, Roel
A1 Heath, Alicia K
A1 Christakoudi, Sofia
A1 Tsilidis, Konstantinos K
A1 Travis, Ruth C
A1 Gunter, Marc J
A1 Keun, Hector C
K1 Amino acids
K1 Endometrial cancer
K1 Lipids
K1 Metabolomics
K1 Obesity
AB Endometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy. To identify additional novel metabolic pathways associated with endometrial cancer we performed metabolomic analyses on pre-diagnostic plasma samples from 853 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC). A total of 129 metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexoses, and sphingolipids) were measured by liquid chromatography-mass spectrometry. Conditional logistic regression estimated the associations of metabolites with endometrial cancer risk. An analysis focusing on clusters of metabolites using the bootstrap lasso method was also employed. After adjustment for body mass index, sphingomyelin [SM] C18:0 was positively (OR1SD: 1.18, 95% CI: 1.05-1.33), and glycine, serine, and free carnitine (C0) were inversely (OR1SD: 0.89, 95% CI: 0.80-0.99; OR1SD: 0.89, 95% CI: 0.79-1.00 and OR1SD: 0.91, 95% CI: 0.81-1.00, respectively) associated with endometrial cancer risk. Serine, C0 and two sphingomyelins were selected by the lasso method in >90% of the bootstrap samples. The ratio of esterified to free carnitine (OR1SD: 1.14, 95% CI: 1.02-1.28) and that of short chain to free acylcarnitines (OR1SD: 1.12, 95% CI: 1.00-1.25) were positively associated with endometrial cancer risk. Further adjustment for C-peptide or other endometrial cancer risk factors only minimally altered the results. These findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.
PB Academic Press
YR 2021
FD 2021-06-01
LK http://hdl.handle.net/10668/17972
UL http://hdl.handle.net/10668/17972
LA en
NO Dossus L, Kouloura E, Biessy C, Viallon V, Siskos AP, Dimou N, et al. Prospective analysis of circulating metabolites and endometrial cancer risk. Gynecol Oncol. 2021 Aug;162(2):475-481.
DS RISalud
RD Apr 8, 2025